Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114299

The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.

C Ferrari, A Penna, A Bertoletti, A Cavalli, A Valli, C Schianchi, and F Fiaccadori

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Ferrari, C. in: JCI | PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Penna, A. in: JCI | PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Bertoletti, A. in: JCI | PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Cavalli, A. in: JCI | PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Valli, A. in: JCI | PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Schianchi, C. in: JCI | PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Fiaccadori, F. in: JCI | PubMed | Google Scholar

Published October 1, 1989 - More info

Published in Volume 84, Issue 4 on October 1, 1989
J Clin Invest. 1989;84(4):1314–1319. https://doi.org/10.1172/JCI114299.
© 1989 The American Society for Clinical Investigation
Published October 1, 1989 - Version history
View PDF
Abstract

14 hepatitis B vaccine recipients who showed high titers of anti-hepatitis B surface antibodies in serum after booster immunization with a polyvalent hepatitis B surface antigen vaccine that contained trace amounts of hepatitis B virus (HBV) preS1 and preS2 envelope antigens were studied for their in vitro T cell response to these antigens. All 14 subjects displayed a significant proliferative T cell response to the S/p25 envelope region encoded polypeptide; 8 also responded to preS1, while only 1 showed a significant level of T cell proliferation to preS2. Limiting dilution analysis demonstrated that the frequency of preS-specific T cells in two of these vaccine recipients was higher than that of S/p25-specific T cells. T cell cloning was then performed and a total of 29 HBV envelope antigen-reactive CD4+ cloned lines were generated from two preS-responsive vaccines. 21 of these lines were S/p25 specific, 7 preS1 specific, and 1 preS2 specific. Taken together, all these results suggest that the preS1 antigen may function as a strong T cell immunogen in man.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1314
page 1314
icon of scanned page 1315
page 1315
icon of scanned page 1316
page 1316
icon of scanned page 1317
page 1317
icon of scanned page 1318
page 1318
icon of scanned page 1319
page 1319
Version history
  • Version 1 (October 1, 1989): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts